Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

This study tests whether adding a drug called trilaciclib — which temporarily protects bone marrow during chemotherapy — to a standard combination of immunotherapy and chemotherapy improves outcomes and reduces side effects in people with newly diagnosed triple-negative breast cancer (TNBC). The treatment is given before surgery (neoadjuvant therapy) to shrink the tumor. **You may be eligible if...** - You are between 18 and 75 years old with newly diagnosed triple-negative breast cancer (stage T1c N1-3 or T2-4 N0-3) - You are scheduled to receive pre-surgical (neoadjuvant) chemotherapy - You have not received any prior cancer drug treatment - You have good organ function and performance status **You may NOT be eligible if...** - Your breast cancer is hormone receptor-positive (HR+) or HER2-positive - Imaging shows your cancer has already spread to distant organs (metastatic) - You have an active autoimmune disease or a history of one (with some exceptions) - You have another active cancer Talk to your doctor to see if this trial is right for you.